About
NaDeNo develops a nanoparticle-based drug delivery platform to encapsulate and locally deliver hard-to-deliver molecules. Its lead candidate, PACAB-002, is being developed to eradicate peritoneal micrometastases in high-grade serous ovarian cancer and is planned to enter Phase I clinical investigation in early 2027.
Explore NaDeNo's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.